Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Simone RossiFrancesco GelsominoRita RinaldiLorenzo MuccioliFrancesca ComitoAlessandro Di FedericoAndrea De GiglioGiuseppe LambertiElisa AndriniVeronica MollicaRoberto D'AngeloFlavia BaccariCorrado ZenesiniPierandrea MadiaEmanuel RaschiPietro CortelliAndrea ArdizzoniMaria GuarinoPublished in: Journal of neurology (2023)
In our large cohort of ICI-treated patients, 2.17% developed PNS-irAEs. Compared to ir-neuropathies, ir-MG/myositis tend to occur earlier from ICI exposure and present a worse response to treatment and a higher mortality.